PMID- 9252717
OWN - NLM
STAT- MEDLINE
DCOM- 19970903
LR  - 20181130
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 17
IP  - 4A
DP  - 1997 Jul-Aug
TI  - Feasibility and toxicity of combination chemotherapy with ifosfamide, 
      vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced 
      non small cell lung cancer.
PG  - 2795-8
AB  - Vinorelbine (VNB) and Ifosfamide (IFO) have recently been proposed for treatment 
      of non small cell lung cancer (NSCLC). The two drugs separately induce response 
      rates in excess of 20% and, when combined, of 32.56%. Cisplatin (DDP) is 
      considered a standard in chemotherapy of NSCLC affected patients. We report data 
      on the feasibility and the toxicity of an IFO, VNB and DDP combination in 
      comparison with IFO, VNB association. Results obtained show that the IFO, VNB, 
      DDP combination has a more severe toxicity profile than the IFO, VNB combination 
      although not to a degree precluding its feasibility. Responses, however, appear 
      somewhat more favorable than in the group treated with the combination IFO, VNB. 
      It is therefore necessary to ascertain if clinical advantages in survival and 
      symptom palliation offered by IFO, VNB, DDP combination outweigh impairment in 
      quality of life due to its significant toxicity.
FAU - Mencoboni, M
AU  - Mencoboni M
AD  - Dipartimento di Medicina Interna, Universita degli Studi di Genova, Italy.
FAU - Lerza, R
AU  - Lerza R
FAU - Castello, G
AU  - Castello G
FAU - Arboscello, E
AU  - Arboscello E
FAU - Barsotti, B P
AU  - Barsotti BP
FAU - Cerruti, A
AU  - Cerruti A
FAU - Ballarino, P
AU  - Ballarino P
FAU - Botta, M
AU  - Botta M
FAU - Bogliolo, G
AU  - Bogliolo G
FAU - Pannacciulli, I
AU  - Pannacciulli I
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 5V9KLZ54CY (Vinblastine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q6C979R91Y (Vinorelbine)
RN  - UM20QQM95Y (Ifosfamide)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Ifosfamide/*administration & dosage
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Vinblastine/administration & dosage/*analogs & derivatives
MH  - Vinorelbine
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1997 Jul-Aug;17(4A):2795-8.